- Home
- NHI vs DNLI Comparison
NHI vs DNLI Comparison
Compare NHI & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHI
- DNLI
- Stock Information
- Founded
- NHI 1991
- DNLI 2013
- Country
- NHI United States
- DNLI United States
- Employees
- NHI N/A
- DNLI N/A
- Industry
- NHI Real Estate Investment Trusts
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NHI Real Estate
- DNLI Health Care
- Exchange
- NHI Nasdaq
- DNLI Nasdaq
- Market Cap
- NHI 3.1B
- DNLI 3.3B
- IPO Year
- NHI 1991
- DNLI 2017
- Fundamental
- Price
- NHI $69.35
- DNLI $21.93
- Analyst Decision
- NHI Buy
- DNLI Strong Buy
- Analyst Count
- NHI 8
- DNLI 13
- Target Price
- NHI $73.00
- DNLI $38.91
- AVG Volume (30 Days)
- NHI 257.8K
- DNLI 1.1M
- Earning Date
- NHI 02-18-2025
- DNLI 02-25-2025
- Dividend Yield
- NHI 5.19%
- DNLI N/A
- EPS Growth
- NHI 19.94
- DNLI N/A
- EPS
- NHI 2.91
- DNLI N/A
- Revenue
- NHI $329,848,000.00
- DNLI N/A
- Revenue This Year
- NHI N/A
- DNLI N/A
- Revenue Next Year
- NHI $14.12
- DNLI $651.24
- P/E Ratio
- NHI $23.82
- DNLI N/A
- Revenue Growth
- NHI 6.05
- DNLI 204.74
- 52 Week Low
- NHI $51.59
- DNLI $14.56
- 52 Week High
- NHI $86.13
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- NHI 46.77
- DNLI 51.28
- Support Level
- NHI $65.13
- DNLI $18.52
- Resistance Level
- NHI $69.55
- DNLI $22.37
- Average True Range (ATR)
- NHI 1.45
- DNLI 1.31
- MACD
- NHI 0.41
- DNLI 0.31
- Stochastic Oscillator
- NHI 93.26
- DNLI 88.57
About NHI National Health Investors Inc.
National Health Investors Inc is a housing and medical facility REIT. The company operates through two reportable segments i.e. Real Estate Investments and Senior Housing Operating Portfolio. The Real Estate Investments segment consists of real estate investments and leases, mortgages, and other notes receivables in independent living facilities, assisted living facilities, entrance-fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment is comprised of two ventures that own the operations of independent living facilities. The company's revenues are derived from rental income, mortgage and other notes receivable interest income, and resident fees and services.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.